Impact of Antiviral Therapy on Gastroesophageal Varices.
Conditions: Chronic Hepatitis C; CirrhosisInterventions: Drug: Pegylated interferon alfa-2a + Ribavirin; Drug: Pegylated interferon alfa-2a + Ribavirin + Boceprevir; Drug: Pegylated interferon alfa-2a + Ribavirin +Telaprevir; Drug: Ledipasvir/Sofosbuvir; Drug: Ombitasvir/paritaprevir/ritonavir+Dasabuvir; Drug: Daclatasvir+Sofosbuvir; Drug: Simeprevir+SofosbuvirSponsor: Parc de Salut MarActive, not recruiting - verified April 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2016 Category: Research Source Type: clinical trials
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
Condition: HCVIntervention: Sponsor: Hoffmann-La RocheActive, not recruiting - verified June 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 11, 2015 Category: Research Source Type: clinical trials
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
Condition: HCVIntervention: Sponsor: Hoffmann-La RocheActive, not recruiting - verified May 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 11, 2015 Category: Research Source Type: clinical trials
